BR112023022264A2 - Esteroide c21-n-pirazolil 19-nor c3,3-dissubstituído e métodos de uso do mesmo - Google Patents

Esteroide c21-n-pirazolil 19-nor c3,3-dissubstituído e métodos de uso do mesmo

Info

Publication number
BR112023022264A2
BR112023022264A2 BR112023022264A BR112023022264A BR112023022264A2 BR 112023022264 A2 BR112023022264 A2 BR 112023022264A2 BR 112023022264 A BR112023022264 A BR 112023022264A BR 112023022264 A BR112023022264 A BR 112023022264A BR 112023022264 A2 BR112023022264 A2 BR 112023022264A2
Authority
BR
Brazil
Prior art keywords
methods
steroid
pyrazolyl
dissubstituted
administering
Prior art date
Application number
BR112023022264A
Other languages
English (en)
Portuguese (pt)
Inventor
Senoaji Adiwijaya Bambang
Handan Gunduz-Bruce
Anne Colquhoun Helen
James Doherty
Martin Jonas Jeffrey
Lisa Dunbar Joi
Alfonso Lasser Robert
Ryan Arnold
Jay Kanes Stephen
Vijayveer Bonthapally
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Publication of BR112023022264A2 publication Critical patent/BR112023022264A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112023022264A 2021-04-29 2022-04-29 Esteroide c21-n-pirazolil 19-nor c3,3-dissubstituído e métodos de uso do mesmo BR112023022264A2 (pt)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202163181743P 2021-04-29 2021-04-29
US202163197025P 2021-06-04 2021-06-04
US202163210810P 2021-06-15 2021-06-15
US202163239096P 2021-08-31 2021-08-31
US202163285812P 2021-12-03 2021-12-03
US202163289506P 2021-12-14 2021-12-14
US202163289520P 2021-12-14 2021-12-14
US202263298601P 2022-01-11 2022-01-11
PCT/US2022/026920 WO2022232504A1 (en) 2021-04-29 2022-04-29 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid for use in treating major depressive disorder and postpartum depression

Publications (1)

Publication Number Publication Date
BR112023022264A2 true BR112023022264A2 (pt) 2024-01-23

Family

ID=81748925

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023022264A BR112023022264A2 (pt) 2021-04-29 2022-04-29 Esteroide c21-n-pirazolil 19-nor c3,3-dissubstituído e métodos de uso do mesmo

Country Status (11)

Country Link
US (1) US20240216395A1 (https=)
EP (1) EP4329770A1 (https=)
JP (2) JP2024515829A (https=)
KR (1) KR20240006026A (https=)
AU (1) AU2022266680A1 (https=)
BR (1) BR112023022264A2 (https=)
CA (1) CA3218072A1 (https=)
IL (1) IL307991A (https=)
MX (1) MX2023012727A (https=)
TW (1) TW202308654A (https=)
WO (1) WO2022232504A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2882708A1 (en) 2012-08-21 2014-02-27 Sage Therapeutics, Inc. Methods of treating epilepsy or status epilepticus
KR102396328B1 (ko) 2013-04-17 2022-05-10 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
EP3504189A1 (en) 2016-08-23 2019-07-03 Sage Therapeutics, Inc. A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid
MA51046A (fr) 2017-12-08 2021-03-17 Sage Therapeutics Inc Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102396328B1 (ko) 2013-04-17 2022-05-10 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
EP3504189A1 (en) 2016-08-23 2019-07-03 Sage Therapeutics, Inc. A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid
WO2019051264A1 (en) * 2017-09-07 2019-03-14 Sage Therapeutics, Inc. NEUROACTIVE STEROIDS AND METHODS OF USE
CA3103421A1 (en) * 2018-06-12 2019-12-19 Sage Therapeutics, Inc. A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof
MX2021006985A (es) * 2018-12-14 2021-09-08 Praxis Prec Medicines Inc Metodos para el tratamiento de la depresión.
KR20230041049A (ko) 2020-07-20 2023-03-23 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드의 제형 및 이의 사용 방법
IL315023A (en) * 2022-02-16 2024-10-01 Sage Therapeutics Inc Neuroactive steroids for treatment of cns-related disorders

Also Published As

Publication number Publication date
JP2024515829A (ja) 2024-04-10
US20240216395A1 (en) 2024-07-04
TW202308654A (zh) 2023-03-01
MX2023012727A (es) 2023-11-08
KR20240006026A (ko) 2024-01-12
IL307991A (en) 2023-12-01
WO2022232504A1 (en) 2022-11-03
JP2025111701A (ja) 2025-07-30
CA3218072A1 (en) 2022-11-03
EP4329770A1 (en) 2024-03-06
AU2022266680A1 (en) 2023-11-02

Similar Documents

Publication Publication Date Title
BR112023022264A2 (pt) Esteroide c21-n-pirazolil 19-nor c3,3-dissubstituído e métodos de uso do mesmo
Tirelli et al. Ozone therapy in 65 patients with fibromyalgia: an effective therapy
MX2025000166A (es) Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y metodos de uso del mismo
ZA202204929B (en) Rimegepant for cgrp related disorders
MX2023012450A (es) Esketamina para el tratamiento de la depresion.
CR20220545A (es) ANTICUERPOS MONOCLONALES HUMANOS DIRIGIDOS CONTRA EL CORONAVIRUS 2 DEL SÍNDROME RESPIRATORIO AGUDO GRAVE (SARS-CoV-2)
MX2023010728A (es) Un esteroide de c21-n-pirazolilo 19-nor c3,3-disustituido para el tratamiento de trastorno depresivo mayor.
CR20190433A (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1
BR112020016331A8 (pt) Métodos para tratar câncer com anticorpos anti-pd-1
JOP20200031A1 (ar) طرق لعلاج الالتهاب العظمي المفصلي باستخدام هلام من كانابيديول عبر الأدمة
BRPI0919020B8 (pt) uso de células de linhagem monocitária enriquecidas para tratar isquemia e para tratar angina pectoris
BR112018067906A2 (pt) métodos de tratamento de depressão usando antagonistas do receptor de orexina-2
BR112022022578A2 (pt) Novas composições e métodos de tratar doença covid-19
HRP20230300T1 (hr) Kombinacije imetelstata i venetoklaksa za liječenje akutne mijeloidne leukemije
BR112022000382A2 (pt) Administração de agonista de sting e inibidores de checkpoint
AR115721A1 (es) Anticuerpos que comprenden un polipéptido insertado en la región marco 3
CL2024003428A1 (es) "formulaciones de anticuerpos anti protofibrillas aß de alta concentración y métodos de uso de las mismas.
MX2022001403A (es) Metodos de administracion de anticuerpos anti-siglec-8 y corticosteroides.
PH12020551726A1 (en) Treatment of atopic dermatitis
MX2021003689A (es) Farmacos precursores de antagonistas del peptido relacionado con el gen para calcitonina (gcrp).
MX2021013222A (es) Metodos para tratar el cancer con un anticuerpo anti-pd-l1.
CL2022002885A1 (es) Modulación de enzimas y vías con compuestos de sulfhidrilo y sus derivados
MY193963A (en) Composition for treating joint diseases and kit containing same
BR112022019338A2 (pt) Tratamento preventivo de enxaqueca
BR112021016913A2 (pt) Método para tratar doenças relacionadas a tnfa